Tudorza Pressair
Tudorza Pressair Uses, Dosage, Side Effects, Food Interaction and all others data.
Tudorza Pressair is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Tudorza Pressair does not prolong the QTc interval or have significant effects on cardiac rhythm.
| Trade Name | Tudorza Pressair |
| Availability | Prescription only |
| Generic | Aclidinium |
| Aclidinium Other Names | Aclidinio |
| Related Drugs | Trelegy Ellipta, ProAir Digihaler, prednisone, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA, Spiriva, Anoro Ellipta |
| Weight | 400mcg/inh, |
| Type | Inhalation powder |
| Formula | C26H30NO4S2 |
| Weight | Average: 484.651 Monoisotopic: 484.161624833 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Tudorza Pressair is an inhaled long-acting anticholinergic used as a maintenance bronchodilator in patients with chronic obstructive pulmonary disease (COPD).
Tudorza Pressair bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Tudorza Pressair is also used to associated treatment for these conditions: Chronic Obstructive Pulmonary Disease (COPD)
How Tudorza Pressair works
Tudorza Pressair is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Tudorza Pressair's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
Toxicity
Most common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.
Food Interaction
No interactions found.Tudorza Pressair Drug Interaction
Moderate: umeclidinium / vilanterol, ipratropium, albuterol / ipratropium, albuterol / ipratropiumUnknown: aspirin, fluticasone / salmeterol, mometasone, mometasone, aspirin, fluticasone / vilanterol, tamsulosin, nitroglycerin, acetaminophen, clopidogrel, albuterol, beclomethasone, budesonide / formoterol, acetaminophen, albuterol, cholecalciferol
Tudorza Pressair Disease Interaction
Major: milk protein allergiesModerate: liver impairment, anticholinergic effects
Volume of Distribution
Following IV administration, the volume of distribution is 300 L
Elimination Route
Bioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;
Half Life
Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.
Clearance
Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)
Elimination Route
Intravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.
Innovators Monograph
You find simplified version here Tudorza Pressair
